Ypsomed Holding AG (LTS:0QLQ) ROCE %: 18.91% (As of Mar. 2026)


LTS:0QLQ Ypsomed Holding AG LTS:0QLQ
82 GF Score
Price CHF359.40
GF Value CHF397.17
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Ypsomed Holding AG ROCE %?

Ypsomed Holding AG LTS:0QLQ -0.94% 82 ROCE % is 18.91% as of Mar. 2026. GuruFocus rates LTS:0QLQ with a GF Score™ of 82/100 and a GF Value™ of CHF397.17 (Modestly Undervalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Ypsomed Holding AG's annualized ROCE % for the quarter that ended in Mar. 2026 was 18.91%.

Ypsomed Holding AG  (LTS:0QLQ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Ypsomed Holding AG ROCE % Related Terms

Ypsomed Holding AG ROCE % Historical Data

* Premium members only.

The historical data trend for Ypsomed Holding AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ypsomed Holding AG ROCE % Chart

Ypsomed Holding AG Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.72 10.46 13.80 14.92 25.97

Ypsomed Holding AG Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.60 12.00 19.00 33.38 18.91
LTS:0QLQ
82GF Score
Ypsomed Holding AG LTS:0QLQ
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ypsomed Holding AG ROCE % Calculation

Ypsomed Holding AG's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=244.15/( ( (1330.341 - 496.186) + (1346.597 - 300.539) )/ 2 )
=244.15/( (834.155+1046.058)/ 2 )
=244.15/940.1065
=25.97 %

Ypsomed Holding AG's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=189.354/( ( (1208.679 - 251.676) + (1346.597 - 300.539) )/ 2 )
=189.354/( ( 957.003 + 1046.058 )/ 2 )
=189.354/1001.5305
=18.91 %

(1) Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 18.91% mean?
Ypsomed Holding AG (LTS:0QLQ) has a ROCE % of 18.91% as of Mar. 2026.
Is Ypsomed Holding AG's ROCE % too high?
Ypsomed Holding AG's current ROCE % is 18.91%. The Medical Devices & Instruments industry median ROCE % is 2.20. Ypsomed Holding AG's value of 18.91% is 759.5% above this industry median. Overall, Ypsomed Holding AG has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ypsomed Holding AG's ROCE % compare to ISRG and BDX?
Ypsomed Holding AG's ROCE % of 18.91% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.20. Ypsomed Holding AG's value of 18.91% is 759.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.20, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ypsomed Holding AG's current ROCE % of 18.91% is 759.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ypsomed Holding AG's current ROCE % is 18.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ypsomed Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Ypsomed Holding AG (LTS:0QLQ) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF397.17, compared to a current price of CHF359.40 — trading 9.5% below its estimated fair value. The current ROCE % is 18.91% and 759.5% above the Medical Devices & Instruments industry median of 2.20. Ypsomed Holding AG's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Ypsomed Holding AG (LTS:0QLQ), the current ROCE % is 18.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ypsomed Holding AG (LTS:0QLQ) Overvalued in 2026?

Based on GuruFocus' analysis, Ypsomed Holding AG stock appears to be undervalued. The current stock price of CHF359.40 is trading 9.5% below its estimated GF Value™ of CHF397.17. GuruFocus considers Ypsomed Holding AG to be Modestly Undervalued.

Key valuation signals for LTS:0QLQ:

  • ROCE %: 18.91%
  • GF Value™: CHF397.17 vs. price of CHF359.40 (9.5% below fair value)
  • GF Score™: 82/100 with 4 warning signs
  • Industry Position: 759.5% above the Medical Devices & Instruments median

No single metric tells the full story. See the LTS:0QLQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ypsomed Holding AG Business Description

Address Brunnmattstrasse 6, Burgdorf, CHE, 3401
Ypsomed Holding AG is a Swiss company that develops and manufactures injection and infusion systems that allow patients to self-administer medication. Specifically, the company focuses on ensuring the ease of diabetes and insulin injection. The company offers various products such as pen needles with a click-on function. The company operates under two reportable segments: Ypsomed Delivery Systems and Ypsomed Diabetes Care.
82GF Score

Get the complete analysis for LTS:0QLQ

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF359.40
Price
CHF397.17
GF Value